BRPI0618245A2 - composto ou um sal farmaceuticamente aceitável do mesmo, e, formulação farmacêutica - Google Patents

composto ou um sal farmaceuticamente aceitável do mesmo, e, formulação farmacêutica Download PDF

Info

Publication number
BRPI0618245A2
BRPI0618245A2 BRPI0618245-3A BRPI0618245A BRPI0618245A2 BR PI0618245 A2 BRPI0618245 A2 BR PI0618245A2 BR PI0618245 A BRPI0618245 A BR PI0618245A BR PI0618245 A2 BRPI0618245 A2 BR PI0618245A2
Authority
BR
Brazil
Prior art keywords
benzo
mmol
carboxylic acid
thiophene
pyrimidin
Prior art date
Application number
BRPI0618245-3A
Other languages
English (en)
Portuguese (pt)
Inventor
Karl Robert Dahnke
Ho-Shen Lin
Chuan Shih
Q May Wang
Bo Zhang
Michael Enrico Richett
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of BRPI0618245A2 publication Critical patent/BRPI0618245A2/pt

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00Antiparasitic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pain & Pain Management (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
BRPI0618245-3A 2005-11-18 2006-11-15 composto ou um sal farmaceuticamente aceitável do mesmo, e, formulação farmacêutica BRPI0618245A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US73809705P 2005-11-18 2005-11-18
US60/738097 2005-11-18
PCT/US2006/060911 WO2007092095A2 (en) 2005-11-18 2006-11-15 [4-(benzo [b] thi0phen-2-yl) pyrimidin-2yl] -amine derivatives as ikk-beta inhibitors for the treatment of cancer and inflammatory diseases.

Publications (1)

Publication Number Publication Date
BRPI0618245A2 true BRPI0618245A2 (pt) 2011-08-23

Family

ID=38345605

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0618245-3A BRPI0618245A2 (pt) 2005-11-18 2006-11-15 composto ou um sal farmaceuticamente aceitável do mesmo, e, formulação farmacêutica

Country Status (27)

Country Link
US (1) US7547691B2 (enExample)
EP (1) EP1989200B1 (enExample)
JP (1) JP2009516697A (enExample)
KR (1) KR100990771B1 (enExample)
CN (1) CN101309918B (enExample)
AR (1) AR057911A1 (enExample)
AT (1) ATE437873T1 (enExample)
AU (1) AU2006337626B2 (enExample)
BR (1) BRPI0618245A2 (enExample)
CA (1) CA2629336A1 (enExample)
CR (1) CR9947A (enExample)
DE (1) DE602006008187D1 (enExample)
DK (1) DK1989200T3 (enExample)
EA (1) EA014426B1 (enExample)
EC (1) ECSP088456A (enExample)
ES (1) ES2329085T3 (enExample)
IL (1) IL190489A0 (enExample)
MA (1) MA30053B1 (enExample)
NO (1) NO20082594L (enExample)
PE (1) PE20070833A1 (enExample)
PL (1) PL1989200T3 (enExample)
PT (1) PT1989200E (enExample)
SI (1) SI1989200T1 (enExample)
TN (1) TNSN08227A1 (enExample)
TW (1) TW200800201A (enExample)
WO (1) WO2007092095A2 (enExample)
ZA (1) ZA200803940B (enExample)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101054325B1 (ko) 2006-03-31 2011-08-04 얀센 파마슈티카 엔.브이. 히스타민 h4 수용체 조절제로서의 벤조이미다졸―2―일 피리미딘 및 피라진
CN101790527A (zh) * 2006-07-20 2010-07-28 凯利普西斯公司 Rho激酶的苯并噻吩抑制剂
WO2008076705A1 (en) * 2006-12-21 2008-06-26 Eli Lilly And Company Imidazolidinonyl aminopyrimidine compounds for the treatment of cancer
JP5166441B2 (ja) * 2006-12-21 2013-03-21 イーライ リリー アンド カンパニー 癌治療用イミダゾリジノニルアミノピリミジン化合物
JP5248600B2 (ja) 2007-05-16 2013-07-31 イーライ リリー アンド カンパニー トリアゾリルアミノピリミジン化合物
AU2008254318B2 (en) 2007-05-16 2012-04-05 Eli Lilly And Company Triazolyl aminopyrimidine compounds
EP2310012B1 (en) 2008-06-30 2015-03-04 Janssen Pharmaceutica N.V. Process for the preparation of substituted pyrimidine derivatives
US9371311B2 (en) 2008-06-30 2016-06-21 Janssen Pharmaceutica Nv Benzoimidazol-2-yl pyrimidine derivatives
KR101123178B1 (ko) * 2009-04-09 2012-06-13 (주)에스메디 2-아릴벤조싸이오펜 유도체 또는 이의 약학적으로 허용가능한 염, 이의 제조방법 및 이를 유효성분으로 함유하는 퇴행성 뇌질환의 진단 또는 치료용 약학적 조성물
KR20120059558A (ko) 2009-08-19 2012-06-08 암비트 바이오사이언시즈 코포레이션 바이아릴 화합물 및 이의 사용 방법
KR20130069641A (ko) 2010-04-27 2013-06-26 허치슨 메디파르마 리미티드 피리미디닐 인돌 화합물
EP2694707B1 (en) 2011-04-07 2018-08-15 Cornell University Monomers capable of dimerizing in an aqueous solution, and methods of using same
US9245773B2 (en) 2011-09-02 2016-01-26 Taiwan Semiconductor Manufacturing Company, Ltd. Semiconductor device packaging methods and structures thereof
CN103159742B (zh) * 2011-12-16 2015-08-12 北京韩美药品有限公司 5-氯嘧啶类化合物及其作为egfr酪氨酸激酶抑制剂的应用
AU2013216935C1 (en) 2012-02-08 2017-12-14 John Emmerson Campbell Heteroaryl compounds and methods of use thereof
US9227978B2 (en) 2013-03-15 2016-01-05 Araxes Pharma Llc Covalent inhibitors of Kras G12C
TWI659021B (zh) 2013-10-10 2019-05-11 亞瑞克西斯製藥公司 Kras g12c之抑制劑
CN105085434B (zh) * 2014-05-09 2018-02-09 上海特化医药科技有限公司 硫乙拉嗪或其中间体的制备方法
WO2017076888A1 (en) 2015-11-03 2017-05-11 Janssen Pharmaceutica Nv 2-[3-(1-methyl-piperidin-4-yl)-propylamino]-pyrimidine-5-carboxylic acids and amides and methods of making the same
ES2996835T3 (en) 2016-07-29 2025-02-13 Sumitomo Pharma America Inc Compounds and compositions and uses thereof
MA45795A (fr) 2016-07-29 2019-06-05 Sunovion Pharmaceuticals Inc Composés et compositions, et utilisations associées
WO2018140512A1 (en) 2017-01-26 2018-08-02 Araxes Pharma Llc Fused bicyclic benzoheteroaromatic compounds and methods of use thereof
US11136308B2 (en) 2017-01-26 2021-10-05 Araxes Pharma Llc Substituted quinazoline and quinazolinone compounds and methods of use thereof
WO2018140599A1 (en) * 2017-01-26 2018-08-02 Araxes Pharma Llc Benzothiophene and benzothiazole compounds and methods of use thereof
US11279689B2 (en) 2017-01-26 2022-03-22 Araxes Pharma Llc 1-(3-(6-(3-hydroxynaphthalen-1-yl)benzofuran-2-yl)azetidin-1 yl)prop-2-en-1-one derivatives and similar compounds as KRAS G12C modulators for treating cancer
KR20200010306A (ko) 2017-05-25 2020-01-30 아락세스 파마 엘엘씨 Kras의 공유적 억제제
US11639346B2 (en) 2017-05-25 2023-05-02 Araxes Pharma Llc Quinazoline derivatives as modulators of mutant KRAS, HRAS or NRAS
AU2018312559B2 (en) 2017-08-02 2022-06-02 Pgi Drug Discovery Llc Isochroman compounds and uses thereof
US12134620B2 (en) 2018-08-01 2024-11-05 Araxes Pharma Llc Heterocyclic spiro compounds and methods of use thereof for the treatment of cancer
WO2020186165A1 (en) 2019-03-14 2020-09-17 Sunovion Pharmaceuticals Inc. Salts of a isochromanyl compound and crystalline forms, processes for preparing, therapeutic uses, and pharmaceutical compositions thereof

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU3752589A (en) * 1988-05-16 1989-12-12 Georgia State University Research Foundation, Inc. Nucleic acid interacting unfused heteropolycyclic compounds
GB0308466D0 (en) * 2003-04-11 2003-05-21 Novartis Ag Organic compounds
MX2007007032A (es) * 2004-12-17 2007-07-04 Amgen Inc Compuestos de aminopirimidina y metodos de uso.

Also Published As

Publication number Publication date
AU2006337626B2 (en) 2012-03-22
PL1989200T3 (pl) 2009-12-31
US7547691B2 (en) 2009-06-16
EP1989200A2 (en) 2008-11-12
ECSP088456A (es) 2008-06-30
ATE437873T1 (de) 2009-08-15
US20080306082A1 (en) 2008-12-11
ES2329085T3 (es) 2009-11-20
DE602006008187D1 (de) 2009-09-10
CR9947A (es) 2008-11-28
NO20082594L (no) 2008-06-10
TNSN08227A1 (en) 2009-10-30
AU2006337626A8 (en) 2008-06-19
JP2009516697A (ja) 2009-04-23
MA30053B1 (fr) 2008-12-01
CN101309918A (zh) 2008-11-19
TW200800201A (en) 2008-01-01
PE20070833A1 (es) 2007-08-27
AR057911A1 (es) 2007-12-26
WO2007092095A2 (en) 2007-08-16
DK1989200T3 (da) 2009-11-09
PT1989200E (pt) 2009-10-12
CN101309918B (zh) 2010-12-29
KR20080059451A (ko) 2008-06-27
AU2006337626A1 (en) 2007-08-16
CA2629336A1 (en) 2007-08-16
IL190489A0 (en) 2008-11-03
EA200801362A1 (ru) 2009-02-27
SI1989200T1 (sl) 2009-12-31
WO2007092095A3 (en) 2007-11-08
ZA200803940B (en) 2009-09-30
EP1989200B1 (en) 2009-07-29
EA014426B1 (ru) 2010-12-30
KR100990771B1 (ko) 2010-10-29

Similar Documents

Publication Publication Date Title
BRPI0618245A2 (pt) composto ou um sal farmaceuticamente aceitável do mesmo, e, formulação farmacêutica
EP2044051B1 (en) Pyridine and pyrazine derivatives as mnk kinase inhibitors
ES2527882T3 (es) Derivados de la 2-aminopirimidina y su uso médico
DK2552909T3 (en) 4-aminopyrimidine derivatives and their use as adenosine A 2A receptor antagonists
ES2328042T3 (es) Derivados de pirazol como unhibidores de los receptores tirosina cinasa.
KR102052670B1 (ko) 키나아제 저해제
ES2273047T3 (es) Fenilaminopirimidinas sustituidas con heteroariloxi como inhibidores de rho-cinasa.
CN1137100C (zh) 能够抑制表皮生长因子受体族之酪氨酸激酶的三环化合物
CN103958498B (zh) 作为lrrk2调节剂的氨基嘧啶衍生物
WO2007070398A1 (en) Polycyclic indazole derivatives that are erk inhibitors
AU2007242594A1 (en) Pyrimidine derivatives as PI3K inhibitors
BR122014026094B1 (pt) compostos de fórmula ii, iii, iv e vi
CN110003219A (zh) 作为irak4调节剂的吡唑并[1,5a]嘧啶和噻吩并[3,2b]嘧啶衍生物
NZ546044A (en) Pyrimidothiophene compounds
CZ304059B6 (cs) Deriváty pyrimidinu a farmaceutický prostredek
BRPI0613452A2 (pt) derivados de 2,4-dianilino pirimidinas, o respectivo preparo, a tìtulo de medicamentos, composições farmacêuticas e notadamente como inibidores de ikk
BRPI0712898A2 (pt) indàis como moduladores de 5-ht6
CN101511824A (zh) 用于治疗糖原合酶激酶(gsk3)相关疾病的咪唑-嘧啶衍生物
ES2345257T3 (es) Tienopirazoles.
CN114105887B (zh) 一种氨基嘧啶衍生物及其制备方法和用途
TW201934546A (zh) 嘧啶類化合物、其製備方法及其醫藥用途
AU2009227111A1 (en) Novel 3-aminoalkyl-1,3-dihydro-2H-indol-2-one derivatives, preparation thereof and therapeutic use thereof.
AU2011307220B2 (en) Phenylquinazoline derivatives
CN101479277A (zh) 作为pi3k抑制剂的嘧啶衍生物
AU2002217269A1 (en) Carbazole derivatives and their use as neuropeptide Y5 receptor ligands

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 8A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2280 DE 16/09/2014.